Journal: Physician Assistant Clinics

Article Title: Severe Acute Respiratory Syndrome Associated Infections

doi: 10.1016/j.cpha.2023.03.002

Figure Lengend Snippet: COVID-19 Vaccine Schedule for People who are NOT immunocompromised. Adapted from Centers for Disease Control and Prevention. ,

Article Snippet: In August 2022, the US FDA announced the EUA of bivalent formulations of the Moderna and Pfizer-BioNTech COVID-19 vaccines for use as a single booster dose at least two months following primary or booster vaccination.

Techniques:

Journal: Physician Assistant Clinics

Article Title: Severe Acute Respiratory Syndrome Associated Infections

doi: 10.1016/j.cpha.2023.03.002

Figure Lengend Snippet: COVID-19 Vaccine Schedule for People Who are Moderately or Severely Immunocompromised. Adapted from Centers for Disease Control and Prevention. ,

Article Snippet: In August 2022, the US FDA announced the EUA of bivalent formulations of the Moderna and Pfizer-BioNTech COVID-19 vaccines for use as a single booster dose at least two months following primary or booster vaccination.

Techniques:

Journal: Physician Assistant Clinics

Article Title: Severe Acute Respiratory Syndrome Associated Infections

doi: 10.1016/j.cpha.2023.03.002

Figure Lengend Snippet: Algorithms for testing to detect SARS-CoV-2 in symptomatic and asymptomatic individuals. Reprinted from Peeling, et al. (A) Preferred testing algorithm for individuals with COVID-19-like symptoms. (B) Testing algorithm for individuals with COVID-19-like symptoms when molecular testing is not available, or results are delayed. (C) Testing algorithm for COVID-19 case finding among asymptomatic individuals.

Article Snippet: In August 2022, the US FDA announced the EUA of bivalent formulations of the Moderna and Pfizer-BioNTech COVID-19 vaccines for use as a single booster dose at least two months following primary or booster vaccination.

Techniques:

Journal: Physician Assistant Clinics

Article Title: Severe Acute Respiratory Syndrome Associated Infections

doi: 10.1016/j.cpha.2023.03.002

Figure Lengend Snippet: Four different patients with varying degrees of COVID-19 pneumonia on CXR predominantly involving the peripheral lungs bilaterally (black arrows). Reprinted from Jacobi, et al.

Article Snippet: In August 2022, the US FDA announced the EUA of bivalent formulations of the Moderna and Pfizer-BioNTech COVID-19 vaccines for use as a single booster dose at least two months following primary or booster vaccination.

Techniques:

Journal: Physician Assistant Clinics

Article Title: Severe Acute Respiratory Syndrome Associated Infections

doi: 10.1016/j.cpha.2023.03.002

Figure Lengend Snippet: Serial radiographs over 7 days in a patient with COVID-19 infection depicting progression of diffuse lung disease that ultimately required intubation. Reprinted from Jacobi, et al.

Article Snippet: In August 2022, the US FDA announced the EUA of bivalent formulations of the Moderna and Pfizer-BioNTech COVID-19 vaccines for use as a single booster dose at least two months following primary or booster vaccination.

Techniques: Infection

Journal: Physician Assistant Clinics

Article Title: Severe Acute Respiratory Syndrome Associated Infections

doi: 10.1016/j.cpha.2023.03.002

Figure Lengend Snippet: CXR (left) and subsequent coronal image from chest CT (right) performed in a patient with COVID-19 and diffuse ground glass and consolidative opacities throughout both lungs. Reprinted from Jacobi, et al.

Article Snippet: In August 2022, the US FDA announced the EUA of bivalent formulations of the Moderna and Pfizer-BioNTech COVID-19 vaccines for use as a single booster dose at least two months following primary or booster vaccination.

Techniques:

Journal: Physician Assistant Clinics

Article Title: Severe Acute Respiratory Syndrome Associated Infections

doi: 10.1016/j.cpha.2023.03.002

Figure Lengend Snippet: Algorithm for Treatment of Nonhospitalized and Hospitalized Patients with COVID-19. , , ,

Article Snippet: In August 2022, the US FDA announced the EUA of bivalent formulations of the Moderna and Pfizer-BioNTech COVID-19 vaccines for use as a single booster dose at least two months following primary or booster vaccination.

Techniques:

Journal: JPGN Reports

Article Title: A Case Series of New-Onset Ulcerative Colitis Following Recent Diagnosis of COVID-19

doi: 10.1097/PG9.0000000000000383

Figure Lengend Snippet: A summary of the 3 patients included in the case series

Article Snippet: COVID-19 vaccination status , 2 Pfizer-BioNTech COVID-19 vaccines , 2 Pfizer-BioNTech COVID-19 vaccines , Unvaccinated.

Techniques: Activity Assay, Vaccines, Histopathology

Journal: Journal of Travel Medicine

Article Title: Maximizing number of doses drawn from multi-dose COVID-19 vaccines by minimizing dead-volume

doi: 10.1093/jtm/taab049

Figure Lengend Snippet: (a) Dead-volumes (μl) of different syringe—needle combinations measured according to standard method NF-EN ISO 7886-1. (b) Actual volume administered by different syringes at 0.3-ml graduation. (c) Number of extractable dose from Pfizer–BioNTech COVID-19 vaccine vials according to different syringe–needle combinations. The data are quoted as the mean ± standard error of mean from at least 5 (a), 50 (b) or 3 (c) independent and blinded measurements. The differences with the theoretical value (0.3 ml) were probed using t -test. * * * * P < 0.0001; * * * P < 0.001; * P < 0.05: volume of one syringe compared with the theoretical volume withdrawn (0.3 ml)

Article Snippet: Based on the standard method NF-EN ISO 7886-1, the volume administered by tuberculin syringes, the dead-volume of several syringe–needle combinations and the number of doses extractable from Pfizer–BioNTech COVID-19 vaccine vials by different syringe–needle combination were measured using Sartorius ME254S-OCE analytical balance as shown in .

Techniques: